 |
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
|
||||
| 2007 JASN IMPACT FACTOR 7.111 | HOME AUTHOR INFO EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP | |||
| CURRENT ISSUE | ARCHIVES | JASN Express | ONLINE SUBMISSION | |
Pathophysiology of Chronic Renal Failure and Complications |
Renal Division, *Department of Internal Medicine and Department of Cell Biology and Physiology, Washington University School of Medicine at Barnes-Jewish Hospital, St. Louis, Missouri.
Correspondence to Dr. Saulo Klahr, Department of Medicine, Barnes-Jewish Hospital (North Campus), 216 South Kingshighway Boulevard, St. Louis, MO 63110-1092. Phone: 314-454-7107; Fax: 314-454-5110; E-mail: sklahr{at}imgate.wustl.edu
Abstract
ABSTRACT. A prevention protocol has demonstrated that bone morphogenetic protein-7 (BMP-7) blunted the development of fibrosis in a rat model of unilateral ureteral obstruction. This prevention protocol also preserved, to an extent, renal function. The prevention protocol was extended and a treatment protocol used to examine if BMP-7 was beneficial at limiting fibrosis of the kidney when the BMP-7 was administered during the progression of fibrotic disease. Animals were distributed into four groups. Group 1 received vehicle, group 2 received enalapril (12.5 mg/kg body wt per d), group 3 received BMP-7 (50 or 300 µg/kg), and group 4 received both the enalapril and the high dose of BMP-7. Rats underwent reversible unilateral ureteral obstruction for 3 d, after which the obstruction was relieved. In the treatment protocol, 300 µg/kg BMP-7 was given after the release of obstruction. Seven days after release of the obstruction and the onset of treatment glomerular filtration rate (GFR), renal blood flow, and various histologic indexes of fibrosis were determined. On a consistent basis, BMP-7 treatment alone was found to be slightly but significantly (P < 0.04 to 0.007) better than enalapril alone or in combination with enalapril at decreasing interstitial volume or tubule atrophy. BMP-7 treatment was slightly but not significantly better (P < 0.09) than enalapril at restoring GFR in the prevention protocol. Treatment with BMP-7 significantly boosted GFR (P < 0.01) above that seen with vehicle treatment. These results suggest that BMP-7 treatment is capable of blunting the progression of fibrotic disease and of decreasing interstitial volume. Importantly, a return of renal function is accelerated by BMP-7 treatment. These results suggest that administration of BMP-7 may be an effective treatment to restore or preserve renal histology and renal function in this experimental model of renal disease.
This article has been cited by other articles:
 |
|
 |
|
  I. Kazama, Z. Mahoney, J. H. Miner, D. Graf, A. N. Economides, and J. A. Kreidberg Podocyte-Derived BMP7 Is Critical for Nephron Development J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2181 - 2191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Marumo, K. Hishikawa, M. Yoshikawa, and T. Fujita Epigenetic Regulation of BMP7 in the Regenerative Response to Ischemia J. Am. Soc. Nephrol., July 1, 2008; 19(7): 1311 - 1320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. De Petris, K. A. Hruska, S. Chiechio, and H. Liapis Bone morphogenetic protein-7 delays podocyte injury due to high glucose Nephrol. Dial. Transplant., December 1, 2007; 22(12): 3442 - 3450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Otani, F. Otsuka, K. Inagaki, M. Takeda, T. Miyoshi, J. Suzuki, T. Mukai, T. Ogura, and H. Makino Antagonistic effects of bone morphogenetic protein-4 and -7 on renal mesangial cell proliferation induced by aldosterone through MAPK activation Am J Physiol Renal Physiol, May 1, 2007; 292(5): F1513 - F1525. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. O. Chen, M. H. Park, M. S. Forbes, B. A. Thornhill, S. C. Kiley, K. H. Yoo, and R. L. Chevalier Angiotensin-converting enzyme inhibition aggravates renal interstitial injury resulting from partial unilateral ureteral obstruction in the neonatal rat Am J Physiol Renal Physiol, March 1, 2007; 292(3): F946 - F955. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Villanueva, C. Cespedes, A. Gonzalez, and C. P. Vio bFGF induces an earlier expression of nephrogenic proteins after ischemic acute renal failure Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2006; 291(6): R1677 - R1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. W. Morrell Pulmonary Hypertension Due to BMPR2 Mutation: A New Paradigm for Tissue Remodeling? Proceedings of the ATS, November 1, 2006; 3(8): 680 - 686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Kim, S.-O. Moon, S. Y. Lee, K. Y. Jang, C.-H. Cho, G. Y. Koh, K.-S. Choi, K.-H. Yoon, M. J. Sung, D. H. Kim, et al. COMP-Angiopoietin-1 Ameliorates Renal Fibrosis in a Unilateral Ureteral Obstruction Model J. Am. Soc. Nephrol., September 1, 2006; 17(9): 2474 - 2483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wang and R. Hirschberg Bone Morphogenetic Protein-7 Signals Opposing Transforming Growth Factor {beta} in Mesangial Cells J. Biol. Chem., May 28, 2004; 279(22): 23200 - 23206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Liu Epithelial to Mesenchymal Transition in Renal Fibrogenesis: Pathologic Significance, Molecular Mechanism, and Therapeutic Intervention J. Am. Soc. Nephrol., January 1, 2004; 15(1): 1 - 12. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Yamashita, A. Maeshima, I. Kojima, and Y. Nojima Activin A Is a Potent Activator of Renal Interstitial Fibroblasts J. Am. Soc. Nephrol., January 1, 2004; 15(1): 91 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zeisberg, C. Bottiglio, N. Kumar, Y. Maeshima, F. Strutz, G. A. Muller, and R. Kalluri Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models Am J Physiol Renal Physiol, December 1, 2003; 285(6): F1060 - F1067. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Davies, R. J. Lund, and K. A. Hruska BMP-7 Is an Efficacious Treatment of Vascular Calcification in a Murine Model of Atherosclerosis and Chronic Renal Failure J. Am. Soc. Nephrol., June 1, 2003; 14(6): 1559 - 1567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wang and R. Hirschberg BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells Am J Physiol Renal Physiol, May 1, 2003; 284(5): F1006 - F1013. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-J. Lee, C. W. Yang, D. C. Jin, Y. S. Chang, B. K. Bang, and Y.-S. Kim Bone Morphogenetic Protein-7 Inhibits Constitutive and Interleukin-1{beta}-Induced Monocyte Chemoattractant Protein-1 Expression in Human Mesangial Cells: Role for JNK/AP-1 Pathway J. Immunol., March 1, 2003; 170(5): 2557 - 2563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Yang and Y. Liu Delayed administration of hepatocyte growth factor reduces renal fibrosis in obstructive nephropathy Am J Physiol Renal Physiol, February 1, 2003; 284(2): F349 - F357. [Abstract] [Full Text] [PDF]
|
|
|
HOME
CURRENT ISSUE
ARCHIVES
JASN Express
ONLINE SUBMISSION
AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP |
Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673
